Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

被引:141
作者
Dorywalska, Magdalena [1 ]
Dushin, Russell [2 ]
Moine, Ludivine [2 ]
Farias, Santiago E. [1 ]
Zhou, Dahui [2 ]
Navaratnam, Thayalan [2 ,3 ]
Lui, Victor [1 ]
Hasa-Moreno, Adela [1 ]
Casas, Meritxell Galindo [1 ]
Tran, Thomas-Toan [1 ]
Delaria, Kathy [1 ]
Liu, Shu-Hui [1 ]
Foletti, Davide [1 ,4 ]
O'Donnell, Christopher J. [2 ]
Pons, Jaume [1 ,5 ]
Shelton, David L. [1 ]
Rajpal, Arvind [1 ,6 ]
Strop, Pavel [1 ,6 ]
机构
[1] Pfizer Inc, Rinat Labs, San Francisco, CA USA
[2] Pfizer Inc, Worldwide Med Chem, Groton, CT 06340 USA
[3] Toronto Res Chem, 2 Brisbane Rd, Toronto, ON M3J 2J8, Canada
[4] 23andMe, 899 W Evelyn Ave, Mountain View, CA USA
[5] Alexo Therapeut, 951 Gateway Blvd Ste 201, San Francisco, CA 94080 USA
[6] Bristol Myers Squibb, 700 Bay Rd Ste A, Redwood City, CA 94063 USA
关键词
PLASMA CARBOXYLESTERASE; CYSTEINE CATHEPSINS; THERAPEUTIC INDEX; CANCER-THERAPY; CATALYTIC-PROPERTIES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; IN-VITRO; DRUG; STABILITY;
D O I
10.1158/1535-7163.MCT-15-1004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors determining the efficacy of antibody-drug conjugates (ADC) in vivo. Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymatic cleavage in rodent plasma. Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma. We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chemical modifications to the linker. While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy. (C) 2016 AACR.
引用
收藏
页码:958 / 970
页数:13
相关论文
共 41 条
  • [11] Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
    Dubowchik, GM
    Firestone, RA
    Padilla, L
    Willner, D
    Hofstead, SJ
    Mosure, K
    Knipe, JO
    Lasch, SJ
    Trail, PA
    [J]. BIOCONJUGATE CHEMISTRY, 2002, 13 (04) : 855 - 869
  • [12] Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
    Ducry, Laurent
    Stump, Bernhard
    [J]. BIOCONJUGATE CHEMISTRY, 2010, 21 (01) : 5 - 13
  • [13] Differential sensitivity of plasma carboxylesterase-null mice to parathion, chlorpyrifos and chlorpyrifos oxon, but not to diazinon, dichlorvos, diisopropylfluorophosphate, cresyl saligenin phosphate, cyclosarin thiocholine, tabun thiocholine, and carbofuran
    Duysen, Ellen G.
    Cashman, John R.
    Schopfer, Lawrence M.
    Nachon, Florian
    Masson, Patrick
    Lockridge, Oksana
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2012, 195 (03) : 189 - 198
  • [14] Production of ES1 Plasma Carboxylesterase Knockout Mice for Toxicity Studies
    Duysen, Ellen G.
    Koentgen, Frank
    Wiliams, Gareth R.
    Timperey, Christopher M.
    Schopfer, Lawrence M.
    Cerasoli, Douglas M.
    Lockridge, Oksana
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2011, 24 (11) : 1891 - 1898
  • [15] Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody-Drug Conjugates
    Farias, Santiago E.
    Strop, Pavel
    Delaria, Kathy
    Casas, Meritxell Galindo
    Dorywalska, Magdalena
    Shelton, David L.
    Pons, Jaume
    Rajpal, Arvind
    [J]. BIOCONJUGATE CHEMISTRY, 2014, 25 (02) : 240 - 250
  • [16] Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan
    Guemei, AA
    Cottrell, J
    Band, R
    Hehman, H
    Prudhomme, M
    Pavlov, MV
    Grem, JL
    Ismail, AS
    Bowen, D
    Taylor, RE
    Takimoto, CH
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (04) : 283 - 290
  • [17] Carboxylesterase inhibitors
    Hatfield, M. Jason
    Potter, Philip M.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (08) : 1159 - 1171
  • [19] Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
    Jeger, Simone
    Zimmermann, Kurt
    Blanc, Alain
    Grunberg, Jurgen
    Honer, Michael
    Hunziker, Peter
    Struthers, Harriet
    Schibli, Roger
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (51) : 9995 - 9997
  • [20] Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    Junutula, Jagath R.
    Raab, Helga
    Clark, Suzanna
    Bhakta, Sunil
    Leipold, Douglas D.
    Weir, Sylvia
    Chen, Yvonne
    Simpson, Michelle
    Tsai, Siao Ping
    Dennis, Mark S.
    Lu, Yanmei
    Meng, Y. Gloria
    Ng, Carl
    Yang, Jihong
    Lee, Chien C.
    Duenas, Eileen
    Gorrell, Jeffrey
    Katta, Viswanatham
    Kim, Amy
    McDorman, Kevin
    Flagella, Kelly
    Venook, Rayna
    Ross, Sarajane
    Spencer, Susan D.
    Wong, Wai Lee
    Lowman, Henry B.
    Vandlen, Richard
    Sliwkowski, Mark X.
    Scheller, Richard H.
    Polakis, Paul
    Mallet, William
    [J]. NATURE BIOTECHNOLOGY, 2008, 26 (08) : 925 - 932